The company leverages two proprietary platform technologies—viral vector-based (ChAdOx/MVA) and synthetic SNAP-Tolerance Immunotherapy (SNAP-TI)—to develop antigen-specific immune tolerance therapies. With $87.8M in cash and runway extending into 2027, Barinthus is advancing lead candidate VTP-1000 in celiac disease with Phase 1 data expected in Q4 2025, while also pursuing partnerships to monetize its broader portfolio.
Cyborg Score Rationale
The company demonstrates promising clinical progress with multiple Phase 1/2 programs and extended cash runway, but faces typical early-stage biotech risks. The pending merger with Clywedog represents a strategic pivot that could unlock value, though execution risk and dilution from the all-stock transaction are concerns. Market cap of $24.5M reflects investor skepticism despite "Strong Buy" analyst ratings.
Top Insights
Company is merging with Clywedog Therapeutics in all-stock transaction; combined entity will list as CLYD on Nasdaq in H1 2026
Lead asset VTP-1000 in celiac disease advancing in Phase 1 AVALON trial with SAD data expected Q4 2025; potential first "curative" immunotherapy for the indication
VTP-300 showed encouraging chronic hepatitis B results with 8 participants achieving HBsAg loss; seeking partner to advance
2024 revenue surged 1766% to $14.97M (likely from milestone payments), while net losses narrowed 16.7% to -$61.07M, indicating operational efficiency
Named Competitors
Inovio Vaccines — DNA immunotherapy platform for infectious disease and oncology
VBI Vaccines — Therapeutic vaccines using eVLP platform technology
CART Therapies — Base editing platform for genetic disease treatment
Recent Developments
(Q2 2025) AVALON Phase 1 trial final cohort initiated for VTP-1000; data expected early Q4 2025
(September 2025) Merger agreement signed with Clywedog Therapeutics; transaction closing targeted H1 2026
(2024) Strategic refocus on immunology/inflammation; revenue increased dramatically from milestone payments
Open the full interactive Barinthus Biotherapeutics plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.